Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Diffuse Large B-Cell Lymphoma (DLBCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02658968
What this trial is testing

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Who this might be right for
Relapsed, Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Nordic Nanovector 18
Large-scale testing (Phase 3)Active Not RecruitingNCT04404283
What this trial is testing

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 239
Testing effectiveness (Phase 2)Looking for participantsNCT07288879
What this trial is testing

DALY II Japan/MB-CART2019.1 for DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell LymphomaCAR T Cell Therapy
Miltenyi Biomedicine GmbH 31
Early research (Phase 1)Active Not RecruitingNCT06014762
What this trial is testing

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc. 120
Testing effectiveness (Phase 2)UnknownNCT05823701
What this trial is testing

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Who this might be right for
Diffuse Large B-Cell Lymphoma
The First Affiliated Hospital of Soochow University 23
Testing effectiveness (Phase 2)Looking for participantsNCT03936153
What this trial is testing

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc. 170
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06886139
What this trial is testing

TRS005 in Patients With CD20-positive R/R DLBCL.

Who this might be right for
CD20-positive Diffuse Large B-Cell Lymphoma
Zhejiang Teruisi Pharmaceutical Inc. 139
Testing effectiveness (Phase 2)Looking for participantsNCT06867536
What this trial is testing

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Lymphoma
Liling Zhang 40
Testing effectiveness (Phase 2)Looking for participantsNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)WithdrawnNCT00829205
What this trial is testing

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Who this might be right for
Lymphoma
Cancer Research UK
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652139
What this trial is testing

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

Who this might be right for
Diffuse Large B Cell Lymphoma
Ruijin Hospital 82
Testing effectiveness (Phase 2)Study completedNCT01238692
What this trial is testing

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B Cell Lymphoma
Sarit Assouline 42
Early research (Phase 1)Study completedNCT05526313
What this trial is testing

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Who this might be right for
Diffuse Large B Cell Lymphoma，DLBCL
Chengdu Zenitar Biomedical Technology Co., Ltd 29
Testing effectiveness (Phase 2)UnknownNCT03367143
What this trial is testing

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma Refractory
Ruijin Hospital 39
Early research (Phase 1)Looking for participantsNCT07121946
What this trial is testing

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedDLBCL - Diffuse Large B Cell LymphomaMantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc. 42
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Testing effectiveness (Phase 2)Study completedNCT02987400
What this trial is testing

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Arbeitsgemeinschaft medikamentoese Tumortherapie 22
Early research (Phase 1)Study completedNCT04231747
What this trial is testing

CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
Juno Therapeutics, a Subsidiary of Celgene 24
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07814001
What this trial is testing

Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

Who this might be right for
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory Large B-cell Lymphoma (LBCL)Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma+3 more
The Lymphoma Academic Research Organisation 55
Next Page